📊 BEIGF Key Takeaways
Investment Thesis
BeOne Medicines demonstrates exceptional fundamental strength with 40.2% revenue growth, accelerating profitability (144.5% net income growth), and industry-leading gross margins of 87.5%. The company maintains fortress-like balance sheet metrics (3.41x current ratio, 0.19x debt/equity) while generating substantial free cash flow of $941.7M, providing significant financial flexibility for future growth initiatives.
BEIGF Strengths
- Exceptional revenue growth of 40.2% YoY indicates strong market demand and successful commercial execution
- Net income growth of 144.5% significantly outpaces revenue growth, demonstrating improving operational efficiency and operating leverage
- Superior gross margin of 87.5% typical of high-value pharmaceutical products with strong pricing power
- Robust free cash flow generation of $941.7M with 17.6% FCF margin provides financial flexibility
- Fortress balance sheet with 3.41x current ratio, low leverage (0.19x debt/equity), and $4.5B cash position
- Strong interest coverage of 9.0x indicates minimal refinancing risk
BEIGF Risks
- Operating margin of 8.4% significantly lags gross margin, suggesting high R&D or SG&A costs that may pressure profitability if revenue growth decelerates
- ROE of 6.6% and ROA of 3.5% are modest relative to revenue scale, indicating inefficient capital deployment or asset-heavy operations
- Pharmaceutical sector exposure to regulatory risks, patent expirations, and clinical trial uncertainties not captured in historical metrics
- High year-over-year growth rates may be unsustainable; deceleration could materially impact market perception and investment thesis
Key Metrics to Watch
- Organic revenue growth rate and product-level performance to assess sustainability of 40.2% growth
- Operating margin expansion/contraction as a proxy for operational efficiency and R&D productivity
- Free cash flow conversion ratio to validate cash generation quality and reinvestment discipline
- R&D spending as percentage of revenue to monitor innovation pipeline health
- Inventory and accounts receivable trends to assess working capital management
BEIGF Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.41x current ratio provides a solid financial cushion.
BEIGF Profitability Ratios
BEIGF vs Healthcare Sector
How BeOne Medicines Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BEIGF Balance Sheet & Liquidity
BEIGF 5-Year Financial Trend
5-Year Trend Summary: BeOne Medicines Ltd.'s revenue has grown significantly by 1,148% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.65 indicates the company is currently unprofitable.
BEIGF Growth Metrics (YoY)
BEIGF Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.0B | $1.3M | $0.08 |
| Q2 2025 | $929.2M | $1.3M | $0.06 |
| Q1 2025 | $751.7M | $1.3M | $0.00 |
| Q3 2024 | $781.3M | -$120.4M | $-0.09 |
| Q2 2024 | $595.3M | -$120.4M | $-0.09 |
| Q1 2024 | $447.8M | -$251.2M | $-0.19 |
| Q3 2023 | $387.6M | $215.4M | $0.15 |
| Q2 2023 | $341.6M | -$348.4M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BEIGF Capital Allocation
BEIGF SEC Filings
Access official SEC EDGAR filings for BeOne Medicines Ltd. (CIK: 0001651308)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 13, 2026 | 4 | xslF345X05/wk-form4_1773437166.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773188062.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773188022.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773187992.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773187917.xml | View → |
❓ Frequently Asked Questions about BEIGF
What is the AI rating for BEIGF?
BeOne Medicines Ltd. (BEIGF) has an AI rating of STRONG BUY with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BEIGF's key strengths?
Exceptional revenue growth of 40.2% YoY indicates strong market demand and successful commercial execution. Net income growth of 144.5% significantly outpaces revenue growth, demonstrating improving operational efficiency and operating leverage.
What are the risks of investing in BEIGF?
Operating margin of 8.4% significantly lags gross margin, suggesting high R&D or SG&A costs that may pressure profitability if revenue growth decelerates. ROE of 6.6% and ROA of 3.5% are modest relative to revenue scale, indicating inefficient capital deployment or asset-heavy operations.
What is BEIGF's revenue and growth?
BeOne Medicines Ltd. reported revenue of $5.3B.
Does BEIGF pay dividends?
BeOne Medicines Ltd. does not currently pay dividends.
Where can I find BEIGF SEC filings?
Official SEC filings for BeOne Medicines Ltd. (CIK: 0001651308) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BEIGF's EPS?
BeOne Medicines Ltd. has a diluted EPS of $0.19.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.